The next frontier in metabolic health: Cagrilintide-Semaglutide and the evolving landscape of therapies

The escalating global burden of obesity and type 2 diabetes (T2D) necessitates highly effective therapies. The novel fixed-dose combination Cagrilintide-Semaglutide (CagriSema), merging a GLP-1 receptor agonist (Semaglutide) with an amylin analog (Cagrilintide), represents a significant therapeutic advance. CagriSema leverages synergistic mechanisms: Semaglutide slows gastric emptying, suppresses glucagon, stimulates insulin, and reduces appetite, while Cagrilintide enhances satiety and further delays gastric emptying via brainstem pathways. Recent REDEFINE trials demonstrate superior efficacy. In REDEFINE 1 (overweight/obesity without T2D), CagriSema achieved mean weight reductions of 20.4-22.7% (vs 2.3-3.0% placebo) at 68 weeks, with 53.6% and 34.7% of patients achieving ≥20% and ≥25% weight loss, respectively. It also significantly improved cardiometabolic parameters, including blood pressure, HbA1c, lipids, and C-reactive protein; 87.7% of prediabetic patients achieved normoglycemia. REDEFINE 2 (overweight/obesity with T2D) showed a 15.7% mean weight reduction and 73.5% achieving HbA1c ≤6.5%. Efficacy significantly surpassed respective monotherapies. The safety profile was consistent with GLP-1 receptor agonists, primarily featuring transient, mild-to-moderate gastrointestinal adverse events (e.g., nausea, 55%), with low discontinuation rates (6-8.4%). This weight loss approaches bariatric surgery outcomes, offering a potent non-surgical alternative. While this rapid evolution toward multi-agonist strategies and oral formulations promises enhanced efficacy, tolerability, and adherence, generating robust long-term safety and efficacy evidence remains imperative.